Abstract 627P
Background
The prevalence of multiple primary neoplasms has been increasing over time, with primary colorectal cancer and primary prostate cancer being a common coexistence. Notably, a primary prostatic cancer was discovered in approximately one-sixth of men who underwent prostate cancer screening prior to rectal cancer excision. Due to a lack of knowledge about the racial disparity factor in this multiple primary malignancy, our study aims to assess the risk of developing primary prostate cancer between African Americans and Caucasians in patients with colorectal cancer.
Methods
We extracted the data from cancer registries in the Surveillance, Epidemiology, and End Results (SEER) database for patients with primary colorectal cancer from 2000-2020. This allowed us to compare the risk of developing primary prostate cancer between African American and Caucasian individuals. We used MP-SIR session to estimate the SIR (standardized incidence ratios) as observed/expected (O/E), and excess absolute risk (EAR) per 10,000 patients using 95% Confidence intervals (CI), with significant result when p <0.05. The latency exclusion period was set at 0 month.
Results
Among 721,385 patients included in the study with primary colorectal cancer, only 8,943 (1.24%) developed primary prostate cancer (Expected= 8,938.87, O/E= 1.00, p >0.05, 95% CI: 0.98-1.02, EAR= 0.01). Out of these cases, approximately 7,340 (82.1%) were Caucasian individuals who developed primary prostate cancer (Expected= 7,633.79, O/E= 0.96, p <0.05, 95% CI: 0.94-0.98, EAR= -1.03), while only 1,603 (17.9%) were African American individuals who developed primary prostate cancer (Expected= 1,305.08, O/E= 1.23, P <0.05, 95% CI: 1.17-1.29, EAR= 7.82). Notably, at the age of 70-74 years, Caucasian individuals exhibited a significant decrease in the risk of developing primary prostate cancer (O/E= 0.91, P <0.05, EAR= -4.12), whereas African American individuals showed a significant increase in risk at this age (O/E= 1.27, P <0.05, EAR= 14.32).
Conclusions
Our results show a higher risk of developing primary prostate cancer in African American patients compared to Caucasian patients. Further research is needed to better understand the race variations on a genetic basis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract